ArticleEuropean journal of medical research2025
Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrative genomic and functional analysis of RAB3B in lung adenocarcinoma: associations with m6A modification and ceRNA networks.Frontiers in pharmacology · 2026Article
- Epigenetic regulation of TNNT1 in gastrointestinal cancers prognostic implications and clinical significance.Clinical epigenetics · 2025Article
- Integrated multi-omics analysis of UL16-binding protein 2 as a prognostic and immunotherapy biomarker for colorectal cancer.Functional & integrative genomics · 2025Article
- The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung adenocarcinoma (LUAD) is one of the most common and lethal tumors. The identification of diagnostic and prognostic biomarkers is essential to improve patient prognosis and treatment outcomes.
methodsThe expression of minichromosome maintenance complex component 8 (MCM8) in 33 cancer types was analyzed using the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression. Tumor and normal tissues in LUAD were compared using TCGA data and validated against four datasets from the Gene Expression Omnibus. MCM8 expression was assessed by immunohistochemistry (IHC) using tissue microarrays. The diagnostic value of MCM8 was assessed by Receiver Operating Characteristic curve analysis, and its prognostic significance was determined by Kaplan-Meier analysis. The CIBERSORT method was used to examine immune infiltration. The association between MCM8 expression and m6A RNA methylation, glycolysis, and ferroptosis was assessed using the GEPIA online tool.
resultsMCM8 is markedly overexpressed in many tumors including LUAD. MCM8 showed high accuracy for the diagnosis of LUAD, with an area under the curve of 0.849 in TCGA dataset. MCM8 overexpression in tumor tissues in LUAD was confirmed by IHC and shown to be associated with decreased overall survival and disease-specific survival. Analysis of immune cell infiltration showed that immune cell populations differed between high and low MCM8 expression groups. MCM8 expression correlated with that of genes associated with m6A RNA methylation, glycolysis, and ferroptosis.
conclusionsMCM8 was identified as a promising diagnostic and prognostic marker in LUAD. The mechanism underlying the effect of MCM8 on cancer development and the immune response remains to be elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.